Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Personalized molecular reprogramming of the tumor immune microenvironment and engineered adoptive cell transfer in synergy with ion-beam radiotherapy for next-generation curative cancer treatments

Ziel

Cancer is a complex multifaceted disease. To conquer cancer, a multidisciplinary approach for rational design of multimodal therapies is imperative. Ground-breaking discoveries in immunotherapy and precision radiotherapy (RT) coupled with initial encouraging results of their combined application, have engendered hope that curative cancer treatments may become possible. Our objective is to harness the full synergistic potential of both modalities through deeper comprehension of the tumor immune microenvironment (TIME) evolution in response to therapy selection pressures. We propose innovative strategies to overcome five major obstacles limiting immunotherapy success: i) tumor camouflage from immune cell recognition, ii) limited immune cell homing and tumor trafficking, iii) paucity of immune activating signals, iv) suppressive signals in the TIME, and v) failure to induce deep memory responses for durable antitumor immunity. The convergence of four research fields, each represented by pioneering scientists, provides a unique opportunity to revolutionize current cancer treatment. To reprogram TIME and create an immunopermissive tumor niche we will employ a broad spectrum of clinical-grade ion beams including protons, helium-, carbon-, and oxygen ions with unique biophysical properties. These novel beam qualities, combined with targeted molecular countermeasures against key tumor immune evasive mechanisms, such as interference with TGFbeta- and integrated stress response pathways, will establish an effective in situ cancer vaccination strategy. In synergy with RT-mediated TIME reprogramming, two adoptive immune cell therapies will be explored: personalized vaccine-induced T cells targeting tumor-specific intracellular neoantigens and chimeric antigen receptor (CAR) T cells engineered to specifically recognize tumor membrane-associated antigens. Our team is uniquely positioned worldwide to develop the next generation of precision immunoradiotherapy.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2025-SyG

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

UNIVERSITATSKLINIKUM HEIDELBERG
Netto-EU-Beitrag
€ 4 325 147,75
Adresse
IM NEUENHEIMER FELD 672
69120 HEIDELBERG
Deutschland
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 4 325 147,75

Begünstigte (4)